NR1D1 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C or lower | Desiccated and protected from light |
| Common analytical method | LC-MS/MS | Detects parent drug and metabolites |
| Solubility class | Lipophilic; soluble in organic solvents | Low aqueous solubility |
| Molecular weight | 437.94 g/mol | Calculated from reported formula |
| Synonyms | SR9009; REV-ERB agonist | Code name used in scientific literature |
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
In classrooms, the requirements in the ASHRAE standard 62.1, Ventilation for Acceptable Indoor Air Quality, would typically result in about 3 air changes per hour, depending on the occupant density. As the occupants are not the only source of pollutants, outdoor air ventilation may need to be higher when unusual or strong sources of pollution exist indoors. ASHRAE Standard 62.1 also provides the Indoor Air Quality Procedure (IAQP), a performance-based alternative to the Ventilation Rate Procedure. Under the IAQP, outdoor airflow and other system design parameters are determined based on factors including contaminant sources, concentration limits, air cleaning, and perceived indoor air acceptability. When outdoor air is polluted, bringing in more outdoor air can actually worsen the overall quality of the indoor air and exacerbate some occupant symptoms related to outdoor air pollution. Generally, outdoor country air is better than indoor city air. The use of air filters can trap some of the air pollutants. Portable room air cleaners with HEPA filters can be used if ventilation is poor or outside air has high level of PM 2.5. Air filters are used to reduce the amount of dust that reaches the wet coils. Dust can serve as food to grow molds on the wet coils and ducts and can reduce the efficiency of the coils. The use of trickle vents on windows is also valuable to maintain constant ventilation. They can help prevent mold and allergen build up in the home or workplace. They can also reduce the spread of some respiratory infections.
== Functional characteristics == With the ability to kill gram-positive and gram-negative bacteria, fungi, spirochetes and some enveloped viruses, cryptdins are classified as broad-spectrum antimicrobial peptides. Although it is the least expressed of the six isoforms, cryptdin-4 is the most bactericidal. Procryptdins, however, are nonbactericidal and thus require degradation of the proregion by MMP-7 for activation. In response to bacterial antigens, Paneth cells release their secretory granules into the lumen of intestinal crypts. There, cryptdins, along with other antimicrobial peptides expressed by Paneth cells, contribute to enteric mucosal innate immunity by clearing the intestinal crypt of potential invading pathogens.
=== For El Niño === 1789-1790 influenza epidemic 1982–83 El Niño event 1997 Pacific hurricane season 1997–98 El Niño event 2014–2016 El Niño event 2015 Pacific hurricane season 2023–2024 El Niño event 2026–2027 El Niño event
== Applications == Hafnium isomers (mainly 178m2Hf) have been considered as weapons that could be used to circumvent the Nuclear Non-Proliferation Treaty, since it is claimed that they can be induced to emit very strong gamma radiation. This claim is generally discounted. DARPA had a program to investigate this use of both nuclear isomers. The potential to trigger an abrupt release of energy from nuclear isotopes, a prerequisite to their use in such weapons, is disputed. Nonetheless a 12-member Hafnium Isomer Production Panel (HIPP) was created in 2003 to assess means of mass-producing the isotope. Technetium isomers 99m43Tc (with a half-life of 6.01 hours) and 95m43Tc (with a half-life of 61 days) are used in medical and industrial applications.
=== Arrest in Arizona === On February 7, 2026, Peters was arrested in Scottsdale, Arizona, on suspicion of dangerous drug possession, with court documents describing him as carrying Adderall and Anavar, and possession of a forged instrument at a bar, after attempting to gain entry using a fake ID. According to officers, he was shown on stream asking patrons at the bar for Adderall. He was released from custody the following day and soon tweeted that the charges were "straight up political persecution". Prosecutors dropped the charges on February 11, 2026, because of the low likelihood of conviction.
Sources: en.wikipedia.org
Upon activation, bAREs ADP-ribosylate any number of eukaryotic proteins; such mechanism is crucial to the instigation of the diseased states associated with ADP-ribosylation. GTP-binding proteins, in particular, are well-established in bAREs pathophysiology. For examples, cholera and heat-labile enterotoxin target the α-subunit of Gs of heterotrimeric GTP-binding proteins. As the α-subunit is ADP-ribosylated, it is permanently in an "active", GTP-bound state; subsequent activation of intracellular cyclic AMP stimulates the release of fluid and ions from intestinal epithelial cells. Furthermore, C. Botulinum C3 ADP-ribosylates GTP-binding proteins Rho and Ras, and Pertussis toxin ADP-ribosylates Gi, Go, and Gt. Diphtheria toxin ADP-ribosylates ribosomal elongation factor EF-2, which attenuates protein synthesis. There are a variety of bacteria which employ bAREs in infection: CARDS toxin of Mycoplasma pneumoniae, cholera toxin of Vibrio cholerae; heat-labile enterotoxin of E. coli; exotoxin A of Pseudomonas aeruginosa; pertussis toxin of B. pertussis; C3 toxin of C. botulinum; and diphtheria toxin of Corynebacterium diphtheriae.
=== 2006–2010 === On November 2, 2006, NHK demonstrated a live relay of a UHDTV program over a 260 kilometer distance by a fiber-optic network. Using dense wavelength division multiplex (DWDM), 24 Gbit/s speed was achieved with a total of 16 different wavelength signals. On December 31, 2006, NHK demonstrated a live relay of their annual Kōhaku Uta Gassen over IP from Tokyo to a 450 inches (11 m) screen in Osaka. Using a codec developed by NHK, the video was compressed from 24 Gbit/s to 180–600 Mbit/s and the audio was compressed from 28 Mbit/s to 7–28 Mbit/s. Uncompressed, a 20-minute broadcast would require roughly 4 TB of storage. The SMPTE first released Standard 2036 for UHDTV in 2007. UHDTV was defined as having two levels, called UHDTV1 (3840 × 2160) and UHDTV2 (7680 × 4320). In May 2007, the NHK did an indoor demonstration at the NHK Open House in which a UHDTV signal (7680 × 4320 at 60 fps) was compressed to a 250 Mbit/s MPEG2 stream. The signal was input to a 300 MHz wide band modulator and broadcast using a 500 MHz QPSK modulation. This "on the air" transmission had a very limited range (less than 2 meters), but shows the feasibility of a satellite transmission in the 36,000 km orbit. In 2008, Aptina Imaging announced the introduction of a new CMOS image sensor specifically designed for the NHK UHDTV project. During IBC 2008 Japan's NHK, Italy's RAI, BSkyB, Sony, Samsung, Panasonic Corporation, Sharp Corporation, and Toshiba (with various partners) demonstrated the first ever public live transmission of UHDTV, from London to the conference site in Amsterdam.
=== Class II === Class II hydrophobins have overall a more conserved amino acid sequence between the different types and, contrary to class I, they have short, regular inter-cysteine spacing. Opposite to class I, the class II hydrophobins monolayer formed at hydrophobic:hydrophilic interfaces is not fibrillar and it is not associated with formation of amyloid-structures, nor with large conformational changes. Nonetheless, high resolution atomic-force microscopy studies revealed the formation of a notable hexagonal repeating pattern over surfaces coated with the class II hydrophobin HBFI, meaning that these proteins are also able to form an ordered network in surface films. The crystal structures or HFBI and HFBII from Trichoderma reesei were the first class II hydrophobins to be determined.
The 1980s MGN W12 F1 engine used rotary valves but never raced. Between 2002 and 2004 the Australian developer Bishop Innovation and Mercedes-Ilmor tested rotary valves for a F1 V10 engine. Bishop Innovations' patent for the rotary valve engine was bought out by BRV Pty Ltd, owned by Tony Wallis, one of the valves original designers. BRV has constructed several functional motors using the rotary valve technology, such as a Honda CRF 450, which had greater torque at both low (17% increase) and high (9% increase) engine speeds, and also produced more brake horsepower up to around 30% more at functional engine speeds. The engine was also considerably smaller and lighter, as the cylinder head assembly was not as large. A company in the UK called Roton Engine Developments made some progress in 2005 with a two-rotor (one for inlet and one for exhaust) single-cylinder Husaberg motorcycle engine. They filed patents and got an example running in 2006, but were backed by MG Rover which subsequently went bust, leaving Roton without enough funds to continue. The designs surfaced some years later in Australia with Engine Developments Australia Pty Ltd. A prototype casting was produced in 2013 on a Kawasaki Ninja 300 parallel twin unit.
The most common adverse effects of Captopril, skin rash and loss of taste, are the same as caused by mercapto-containing penicillamine. Therefore, a group of researchers aimed at finding potent, selective ACE inhibitors that would not contain a mercapto (SH) function and would have a weaker chelating function. They returned to work with carboxyl compounds and started working with substituted N-carboxymethyl-dipeptides as a general structure (R-CHCOOH-A1-A2). According to previous research they assumed that cyclic imino acids would result in good potency if substituted on the carboxyl terminus of the dipeptide. Therefore, substituting A2 with proline gave good results. They also noted that according to the enzyme's specificity imino acids in the position next to the carboxyl terminus would not give a potent compound. By substituting R and A1 groups with hydrophobic and basic residues would give a potent compound. By substituting –NH in the general structure resulted in loss of potency which is consistent to the enzyme's need for a –NH in corresponding position on the substrates. The results were 2 active inhibitors: Enalaprilat and Lisinopril. These compounds both have phenylalanine in R position which occupies the S1 groove in the enzyme. The result was thus these two new, potent tripeptide analogues with zinc-coordinating carboxyl group: Enalaprilat and Lisinopril.
Sources: en.wikipedia.org
== Antibody elution == Antibody elution is the process of removing antibodies that are attached to their targets, such as the surface of red blood cells. Techniques include using heat, a freeze-thaw cycle, ultrasound, acids, or organic solvents.
Traditionally, Parkinson's disease has been considered a non-genetic disorder. However, between 15 and 25% of people with PD report familial connections who have PD, and from 10 to 20% have a first-degree relative with PD. No single-gene mutation in PD causes PD, but multiple genetic factors can increase susceptibility and the risk of developing either familial or sporadic PD. More penetrant PD mutations with a higher risk of developing the disease, tend to be rare but are often associated with familial PD (e.g. rare SNCA variants). A second group of variants (including GBA and LRRK2 variants) are uncommon and carry an intermediate level of risk in a significant minority of PD cases. A third group of genetic variants occur often but carry low risk. Unequivocal links to PD pathogenesis have been found for mutations in at least six genes: LRRK2, SNCA, and VPS35 (dominant forms) and PRKN/Parkin, PINK1, and PARK7/DJ1 (recessive forms). The most extensively studied PD-related genes are LRRK2 and SNCA. At least 16 genes display "causal" variants associated with genetic predisposition for PD, through higher familial inheritance of PD or development of early-onset PD symptoms. An additional 44 novel risk loci have been associated with sporadic PD. Both autosomal dominant and autosomal recessive gene mutations have been implicated in the development of PD. Autosomal dominant genes include SNCA (PARK1, PARK4, NCAP) and VPS35 (PARK17, MEM3), which are rare but highly penetrant, and CHCHD2. LRRK2 (PARK8, DARDARIN) and GBA (GBA1) are pathogenic but have variable penetrance.
== Taxonomy == Arnebia densiflora was first described by Carl Friedrich von Ledebour. It was first published in Flora Rossica Enumeratio sive Plantarum in Totivs Imperii Rossici Provinciis europaeis, Asiaticis, et americanis Hucusque Observatarum 3 (1.8): 140. 1847
=== Mapping === The gene was mapped to human chromosome 5. Gene specific primer pairs resulted in PCR amplification of a product matched by size to a hybrid-mapping panel containing only chromosome 5 as its human genetic material. The product DNA sequence matched pre-established gene markers specific to this chromosome. Exact gene cytogenic position was determined by mapping to an artificial chromosomal construct containing the gene via fluorescence in situ hybridization. The exact MTRR gene location was mapped to 5p15.3-p15.2.
== Variants == SDS-PAGE is the most widely used method for gel electrophoretic separation of proteins. Two-dimensional gel electrophoresis sequentially combines isoelectric focusing or BAC-PAGE with a SDS-PAGE. Native PAGE is used if native protein folding is to be maintained. For separation of membrane proteins, BAC-PAGE or CTAB-PAGE may be used as an alternative to SDS-PAGE. For electrophoretic separation of larger protein complexes, agarose gel electrophoresis can be used, e.g. the SDD-AGE. Some enzymes can be detected via their enzyme activity by zymography.
Sources: en.wikipedia.org
Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.
Research samples are typically kept frozen, desiccated, and protected from light. Stock solutions are often aliquoted to reduce freeze-thaw cycles.
High-performance liquid chromatography and nuclear magnetic resonance are standard for purity and identity. Mass spectrometry confirms molecular weight.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.